NVO - Novo Nordisk's Weight Loss Drugs Ozempic Wegovy Show Promise For Diabetic Patients Undergoing Hip Replacement | Benzinga
Preliminary findings presented at an orthopedic surgeons’ meeting on Monday indicate that new drugs designed for diabetes and weight loss could benefit patients undergoing hip replacement.
In a comprehensive study focusing on using Novo Nordisk A/S’s (NYSE:NVO) Ozempic (semaglutide), prescribed for diabetes, researchers observed a significant 44% reduction in the likelihood of post-implantation joint infections.
The study, conducted at a New York City hospital, involved 9,465 diabetic patients who underwent total hip arthroplasty, with 1,653 taking Ozempic.
Patients on Ozempic also exhibited a 32% decrease in the odds of hospital readmission, with no associated rise in postoperative complications.
Most subjects also grappled with obesity, as highlighted by study leader Dr. Matthew Magruder from Maimonides Medical Center in Brooklyn.
Another study further supports the ...